Home > Stocks > Commentaries
Drug Roundup: October 16, 2014
There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Eli Lilly & Co. (LLY), Bristol-Myers Squibb (BMY), Merck & Co. (MRK), Pfizer Inc. (PFE), Actavis plc. (ACT), AbbVie Inc. (ABBV), and Shire plc. (SHPG). Read more
Dogs Of The Dow: 2014 Third Quarter Review
The equity bull market is now somewhat long in the tooth and, as it makes its way through its sixth straight year, the going has not been as easy as it was in the early part of this run. The Dow Jones Industrials have posted solid, if relatively unexciting, numbers through the first three quarters, but the Dogs have maintained an edge throughout most of that period. Read more
Restaurant Roundup: October 9, 2014
There are a handful of companies in the restaurant space that do not report results on a calendar-year basis, so we will take a look at their recent performances to try and get a better picture of what is to come in the next few weeks. Read more
The Great International Expansion of Gaming

Gaming’s growth in Macau, China has made many Asian countries envious. Eager to replicate the success of the world’s biggest gaming market, a number of nations in the Pacific region have/are contemplating the approval for integrated casino resorts.  None of them offer the potential of Japan, whose population possess high earnings and have a proclivity for gaming. Moreover, should the economic juggernaut approve the building of such establishments, it is apt to attract gaming enterprises from across the world.

Read more
Technology Round Up: October 2, 2014

There have been several noteworthy developments in the technology space recently. Some of these will likely have a material impact on the companies in the sector and the markets they serve. Companies featured include Sony (SNE), Apple (AAPL), Samsung, and eBay (EBAY).

 

Read more
Running on Fumes: The Future of Ethanol as a Fuel Source
Ethanol has fallen out of grace in recent years. Should investors be excited about new developments in this once promising alternative fuel? Read more
Retail Roundup: September 25, 2014
Preliminary results for the recently ended back-to-school season look to be better-than-originally-expected for most in the retail space. Indeed, August sales were said to have increased 0.3%, ahead of Wall Street’s call. Although the advance was minor, overall, many are speculating that the August outperformance may be an inflection point, and that an improved housing market, lower fuel costs, and more favorable job market have helped lift consumer confidence to levels not seen in recent memory. Read more
Oil Price View Goes From Glass Half Full To Half Empty
Oil prices have pulled back as demand growth has eased and supplies have increased. But volatility is par for the course in the drilling business, and the pendulum may well swing back the other way before too long. Read more
Drug Roundup: September 18, 2014
There have been several noteworthy developments in the drug space recently, which will likely have a material impact on the companies in this sector and the markets they serve. Companies mentioned in this review include Pfizer Inc. (PFE), AstraZeneca (AZN), Merck & Co. (MRK), AbbVie Inc. (ABBV), and Eli Lilly (LLY) Read more
The Dogs Lost Some Steam In The August Heat, But Maintained Their Lead
As the U.S. bull market for equities marches toward a sixth straight year, major benchmarks such as the S&P 500 and Dow Jones Industrials have clawed their ways to new highs. However, the numbers alone don’t tell the whole story. The Dogs of the Dow strategy, unsurprisingly, is also benefitting from the upswing, advancing every month with the exception of January. Although August found the pack lagging the gains posted by the 30 Dow Industrials as a whole, year-to-date performance has maintained a relatively comfortable lead. Merck and Microsoft logged the biggest gains last month, but Intel’s stock has outrun the Dogs (and the rest of the Dow components, for that matter) by a sizable margin so far this year. Read more
[First] [Previous] [Next] [last]
Loading...
Free stock reports
The Value Line 600
Value Line is regarded as the best independent research available. More than just recommendations, Value Line provides the rationale behind its picks for greater understanding.
- Don D., California